Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a heart drug tame stress inflammation?

NCT ID NCT06263452

Knowledge-focused Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single dose of the beta-blocker propranolol can reduce inflammation caused by psychological stress. Researchers will measure immune markers and brain activity in 120 healthy young adults before and after a stressful task. The goal is to understand the link between stress and heart disease risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Propranolol (a beta-blocker)
What this could lead to
If successful, this study could reveal how stress triggers inflammation and point toward new treatments to lower heart disease risk.
What could go wrong
This is an early-phase, small study (120 people) focused on understanding mechanisms, not testing a treatment. Results may not lead to direct therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages 18-30 years * Right-handed * Fluent in English reading, writing, and speaking at least at a 10th grade level * Body mass index (BMI) less than or equal to 35 kg/m\^2 Exclusion Criteria: Assessed as screening, reassessed at Session I: * Non-removeable metal devices/implants/objects in the body * Severe claustrophobia (assessed by self-report) * Currently pregnant * Left-handed * Body mass index (BMI) greater than 35 kg/m\^2 * History of fainting spells or any heart condition * History of or present low resting heart rate (\< 60 BPM) and/or low blood pressure (systolic blood pressure \< 80mmHg) * Self-reported physical illnesses: diabetes, cardiovascular diseases, high blood pressure, inflammatory bowel diseases, rheumatoid arthritis, asthma, autoimmune disease, Crohn's disease, ulcerative colitis, lupus * Any self-reported diagnosed mental illness * Current use of prescription medications (except hormonal contraceptives) * Current or recent regular nicotine/tobacco use (cigarettes, e-cigarettes, vape, chewing tobacco, nicotine gum) * Current regular (daily or almost daily) recreational drug use = 4 or more times per week Instructed against during Session I, reassessed at Session II: * Received any vaccine within the past two weeks * Severe sleep disturbance (3-4 hours of sleep loss) the night before Session II * Vigorous physical activity on the day of Session II * Acute illness or allergy symptoms on the day of Session II * Usage of over-the-counter medications on the day of Session II * Usage of recreational drugs within 48 hours of Session II * Usage of alcohol on the day of Session II

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Social Neuroscience and Health Laboratory

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.